Skip to main content

Advertisement

Table 3 Summary of safety data

From: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

  Placebo Etoricoxib 90 mg Naproxen 1000 mg
  (N = 357) (N = 353) (N = 181)
  n (%) n (%) n (%)
Number of patients:    
   With any drug-related clinical adverse event 55 (15.4) 82 (23.2) 35 (19.3)
   With any serious clinical adverse event 3 (0.8) 7 (2.0) 3 (1.7)
   Discontinued due to clinical adverse event 6 (1.7) 9 (2.5) 5 (2.8)
  1. p < 0.05 vs placebo. 
  2. Serious adverse events were: placebo (3 patients) – thrombophlebitis, atrial fibrillation, and pneumothorax; etoricoxib (7 patients) – pulmonary embolism, angina pectoris, thyroid cancer, duodenal ulcer, hip pain, femoral fracture, and traumatic arthropathy plus corneal degeneration (in the same patient); naproxen (3 patients) – hypertension, intervertebral disc displacement, and retinal detachment.